Core Insights - Firefly Neuroscience, Inc. has made significant advancements in Alzheimer's research, focusing on differentiating between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia through accessible diagnostic methods [1][2] Group 1: Research Findings - The combination of EEG/ERP and volumetric magnetic resonance imaging (vMRI) provides the most accurate results for diagnosing cognitive impairments, achieving an accuracy of approximately 87% (AUC=0.87) when both methods are used together [2] - Key EEG measures identified include reaction time, commission errors, and P300b amplitude, which alone can categorize subjects with around 80% accuracy (AUC=0.79) [2] - The left temporal lobe size is a significant MRI predictor of cognitive issues, with smaller sizes correlating to higher cognitive impairment [2] Group 2: Company Developments - Firefly's recent acquisition of Evoke Neuroscience has enabled the integration of research teams to leverage a proprietary database of over 180,000 standardized EEG/ERP assessment records [3] - The company is working to link its breakthrough cognitive brain age biomarker with the findings from the recent study, aiming for a proactive approach to early screening and staging of Alzheimer's disease [3] - Firefly's FDA-cleared Brain Network Analytics (BNA™) technology is set to revolutionize diagnostic and treatment monitoring methods for various neurological and mental disorders [4][5] Group 3: Market Position and Strategy - Firefly targets pharmaceutical companies involved in drug research and clinical trials, as well as medical practitioners for clinical use of its BNA™ technology [4] - The company has built a comprehensive database of brain wave tests over the past 15 years, securing patent protection and achieving FDA clearance for its technologies [4][5]
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients